Leisure Acquisition and Ensysce Biosciences Ink Merger Agreement

Leisure Acquisition

Leisure Acquisition announced today that it has signed a definitive agreement to acquire Ensysce Biosciences. The transaction reflects an enterprise valuation for Ensysce of $207 million, including the company’s existing convertible indebtedness, but excluding transaction expenses as well as the impact of Leisure’s sponsor shares and subject to certain closing adjustments.    

Consideration paid to Ensysce’s shareholders for their interests will consist of shares of Leisure common stock issued at $10 per share. Assuming none of Leisure’s shares of common stock are redeemed for cash in trust, Ensysce’s existing shareholders would own approximately 71% of the combined company’s outstanding common stock at closing.  Certain liabilities of Ensysce are expected to remain in place, and all of Ensysce’s convertible debt will be converted into common stock of the combined company. Read more.

Total
0
Shares
Related Posts
IPO
Read More

Accretion Acquisition Files for $150M IPO

Accretion intends to acquire a business involved in the energy value chain, including upstream, water management, gas and vapor capture, energy transition related systems, midstream, oil and gas-related software, commodity risk management or oil and gas services.